MeiraGTx, a clinical-stage gene therapy company with a global footprint, is focused on developing potentially curative treatments for patients living with serious diseases.
We currently have six ongoing clinical programs, one compassionate use program and a broad pipeline of preclinical and research programs.
While we are initially focusing on diseases of the eye, salivary gland and central nervous system, we believe gene therapy has broad potential to treat a range of conditions.
Each day we work to improve the lives of patients through cutting-edge science designed to treat their specific disease. We believe each patient deserves the best treatment possible and with our highly flexible gene therapy platform and manufacturing process, we believe we can deliver on that promise.